GlassScriptPhysician profile
Suresh K Krishnan
NPI 1760598668
$9,822.93
in general payments reported to CMS, 2019-2025
37 companies · $277 in 2025
The $277 reported for 2025 was less than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,348 · 2020: $557 · 2021: $3,177 · 2022: $1,219 · 2023: $1,090 · 2024: $155 · 2025: $277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,522.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,522.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spinal Simplicity, LLC | $2,432.05 | 2021-2022 | |
| Abbott Laboratories | $1,857.04 | 2019-2023 | Proclaim |
| Medtronic, INC. | $1,080.84 | 2021-2025 | Intellis Adaptivestim |
| Vertiflex, INC. | $1,059.43 | 2019 | |
| Medtronic USA, INC. | $547.21 | 2019-2020 | |
| Nevro Corp. | $392.08 | 2019-2024 | Senza |
| Abbvie INC. | $311.74 | 2021-2024 | |
| Tersera Therapeutics LLC | $233.37 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $217.52 | 2019-2023 | Ztlido |
| Collegium Pharmaceutical, INC. | $147.19 | 2022-2023 | Xtampza, Belbuca |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $144.58 | 2019-2023 | Relistor |
| Boston Scientific Corporation | $125.44 | 2019 | |
| Galderma Laboratories, L.P. | $125.00 | 2021 | |
| Pfizer INC. | $109.70 | 2019-2024 | |
| Spr Therapeutics, INC | $108.51 | 2025 | Sprint Pns System |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $105.40 | 2023 | Qutenza |
| Allergan, INC. | $89.43 | 2019-2022 | |
| Grt US Holding, INC. | $87.00 | 2022 | |
| Vertos Medical, INC. | $64.21 | 2019-2020 | |
| Stimwave Technologies Incorporated | $63.88 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $53.89 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $52.10 | 2022 | |
| Nalu Medical, INC. | $41.36 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $41.07 | 2023 | Seglentis |
| Kaleo, INC. | $37.80 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $37.77 | 2020-2021 | |
| Valinor Pharma, LLC | $35.05 | 2023 | Movantik |
| Ibsa Pharma INC. | $34.11 | 2022-2023 | Tirosint, Licart |
| Azurity Pharmaceuticals, INC. | $33.77 | 2023 | Horizant |
| Stryker Corporation | $28.89 | 2024 | Spinejack |
| Orthogenrx INC. | $26.81 | 2019 | |
| Arbor Pharmaceuticals, INC. | $25.81 | 2022 | |
| Impel Pharmaceuticals INC. | $18.01 | 2023 | Trudhesa |
| Novartis Pharmaceuticals Corporation | $16.84 | 2020 | |
| Lundbeck LLC | $13.52 | 2023 | Vyepti |
| Virtus Pharmaceuticals LLC | $13.51 | 2021 | |
| Zyla Life Sciences, INC. | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suresh Krishnan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.